Medical Research
60 articles on Medical Research, written by Shotlee and medically reviewed for clinical accuracy.
Popular Weight-Loss Drugs Ozempic and Wegovy May Slow Biological Aging
A new clinical trial suggests that semaglutide, the active ingredient in Ozempic and Wegovy, may help slow biological processes associated with aging in adults with HIV.
8 min read
GLP-1 Weight-Loss Drugs Linked to Lower Risks of Addiction and Overdose
Explore the groundbreaking research linking GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, to a reduced risk of substance use disorders and fewer addiction-related emergencies.
8 min read
Bariatric Surgery Shows 5x More Weight Loss Than GLP-1s in Real-World Study
A groundbreaking real-world comparison study presented at the ASMBS 2025 Annual Scientific Meeting found that bariatric surgery resulted in approximately five times more weight loss compared to popular GLP-1 receptor agonist medications over a two-year period. This research highlights important considerations for patients and healthcare providers navigating weight management options.
7 min read
Mounjaro's Impact on Food Cravings: A Case Study
A groundbreaking case study involving deep brain activity recordings has shed light on how tirzepatide, known as Mounjaro and Zepbound, impacts the brain's reward center and its connection to food cravings and loss of control eating.
8 min read
Managing Ozempic and Wegovy Weight Loss Side Effects: Nausea and Beyond
New research is shedding light on how GLP-1 medications, including popular drugs like Ozempic and Wegovy, influence brain pathways that control nausea, thirst, and reward-driven behaviors. This article delves into these findings and discusses potential strategies for managing common side effects.
7 min read
Semaglutide (Ozempic, Wegovy) Offers Heart Protection Beyond Weight Loss
A groundbreaking study published in The Lancet demonstrates that semaglutide, the active ingredient in Ozempic and Wegovy, provides substantial cardiovascular protection independent of the amount of weight lost. This finding reshapes our understanding of how these GLP-1 receptor agonists benefit heart health.
7 min read
The Next Ozempic: A 4-in-1 Breakthrough for Lasting Weight Loss
While Ozempic and similar GLP-1 agonists have revolutionized weight management, new research from Tufts University is exploring a novel 4-in-1 peptide that targets four hormone receptors for potentially greater efficacy and fewer side effects, moving closer to the gold standard of bariatric surgery.
6 min read
Ozempic and Wegovy Linked to Reduced Violent Behavior in New Study
Beyond their well-known benefits for weight loss and diabetes management, popular GLP-1 medications such as Ozempic and Wegovy are now being studied for their potential impact on violent behavior. Emerging research from Rutgers University indicates a surprising link between these drugs and a reduction in actions associated with violence.
6 min read
Semaglutide Linked to Fewer Bone Fractures Despite Greater Weight Loss
Discover how semaglutide, a popular GLP-1 medication, shows a surprising benefit in a recent study, potentially reducing bone fracture risk even as it aids in substantial weight loss for individuals with type 2 diabetes.
7 min read
Ozempic vs. Jardiance: Better Heart Protection for Diabetics with AFib
A new study compares GLP-1 and SGLT-2 inhibitors in patients with type 2 diabetes and atrial fibrillation, revealing significant differences in heart health outcomes.
7 min read
Ozempic, Wegovy, Mounjaro: How Do They Affect Mental Health?
New research sheds light on the neuropsychiatric effects of popular weight loss medications like semaglutide and tirzepatide. Discover how these treatments may influence anxiety, depression, and other mental health outcomes.
7 min read
Beyond Weight Loss: How GLP-1s Like Ozempic May Impact Impulse and Behavior
While known for diabetes and weight management, GLP-1 receptor agonists like Ozempic and Wegovy might have a surprising effect on impulse control and behavior, according to emerging research.
6 min read
Ozempic & Wegovy: Surprising Bone Health Benefit Uncovered
While GLP-1 agonists like Ozempic and Wegovy are celebrated for weight loss and blood sugar control, a recent study suggests a surprising benefit: improved bone health and a reduced risk of fractures in adults with Type 2 diabetes.
7 min read
Beyond the Dose: Why Some GLP-1s Fall Short & What It Means
A groundbreaking Stanford study reveals a genetic reason why approximately 10% of individuals don't respond as expected to GLP-1 receptor agonists, impacting treatments for diabetes and weight loss.
7 min read
Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?
Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.
7 min read
GLP-1 Drugs & Your Knees: New Research on Joint Health
Discover how GLP-1 medications, known for weight loss, may also significantly reduce the need for knee replacement surgery. This article delves into the latest research and its implications for joint health.
7 min read
Beyond Ozempic: A New Pill Targets Fat Metabolism Without Appetite Loss
A groundbreaking pill developed by researchers at Karolinska Institutet and Stockholm University offers a new avenue for treating type 2 diabetes and obesity. Unlike injectable GLP-1 agonists, this oral medication targets muscle metabolism to enhance fat burning and improve blood sugar control, aiming to circumvent common side effects.
7 min read
Beyond the Headlines: New GLP-1 Side Effects Uncovered on Reddit?
A groundbreaking study utilized AI to sift through over 400,000 Reddit posts, uncovering potential new side effects associated with popular GLP-1 medications such as Ozempic, Wegovy, and Mounjaro. This research highlights the growing role of real-world data in understanding medication safety.
8 min read
Beyond Weight Loss: The Expanding Horizon of GLP-1 Therapies
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
8 min read
Ozempic, Wegovy: New Insights Into Brain Receptors Could Revolutionize Dosing
Millions are experiencing transformative weight loss with GLP-1 agonists like Ozempic and Wegovy. However, many encounter plateaus. Groundbreaking research from the NIH is shedding light on why this happens within the brain's appetite control centers, potentially paving the way for more effective and personalized treatment plans.
6 min read
Ozempic & Wegovy: Unlocking the Brain's Fading Appetite Signals
A groundbreaking study reveals that the effectiveness of semaglutide, the active ingredient in popular weight loss medications like Ozempic and Wegovy, may be linked to the duration and intensity of chemical signals within specific brain cells. This research sheds light on why weight loss can plateau and offers clues for developing more sustained and effective future therapies.
6 min read
Beyond Weight Loss: Do GLP-1 Drugs Impact Mental Health?
New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.
7 min read
Semaglutide vs. Tirzepatide: Unpacking New Diabetes Insights & Long COVID Clues
Discover how new studies are reshaping our understanding of Type 2 diabetes management with tirzepatide and offering critical insights into the biological drivers of Long COVID's persistent neurological symptoms.
6 min read
Semaglutide Plateaus: New Brain Discovery Could Boost Weight Loss Results
New research from the NIH reveals how semaglutide signaling in the brain affects weight loss plateaus, offering hope for improved efficacy and dosing strategies.
7 min read
Ozempic Side Effects: AI Uncovers Hidden Symptoms on Reddit
Researchers at the University of Pennsylvania utilized artificial intelligence to analyze hundreds of thousands of Reddit posts, uncovering patient-reported side effects of GLP-1 medications that traditional clinical trials often overlook.
8 min read
Zabopegdutide Shows Promise in MASH and Fibrosis: A New Hope for Liver Health
New data from D&D Pharmatech's Phase 2 trial for zabopegdutide, a GLP-1/glucagon dual receptor agonist, reveals promising results for patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. This development positions zabopegdutide as a potential contender in a growing market.
7 min read
Beyond Weight Loss: GLP-1s Show Promise Against Inflammation
Initially celebrated for their weight-loss efficacy, GLP-1 receptor agonists are now revealing a broader therapeutic scope. Emerging research suggests these powerful medications may offer significant benefits in combating inflammation and tissue damage, potentially transforming the management of chronic diseases.
6 min read
Wegovy and Eye Stroke Risk: What You Need to Know
A recent study has raised questions about a rare but serious eye condition linked to Wegovy. Learn more about ischemic optic neuropathy (ION) and what this research means for patients using GLP-1 medications.
7 min read
Beyond Weight Loss: Could Ozempic and Wegovy Help Your Arthritis?
Popular GLP-1 medications, known for their weight loss efficacy, are now showing potential to combat arthritis inflammation. Discover what this groundbreaking research means for joint health.
7 min read
GLP-1 Drugs and Vision Loss: Understanding NAION Lawsuits
Recent lawsuits are raising serious questions about the potential for GLP-1 medications, widely used for diabetes and weight loss, to cause a rare but devastating eye condition known as NAION, leading to permanent vision loss. This article delves into the allegations, scientific evidence, and ongoing legal proceedings.
6 min read
GLP-1 Drugs: A New Frontier in Addiction Treatment?
Could the same medications revolutionizing weight loss and diabetes management also hold the key to treating addiction? Emerging research suggests GLP-1 receptor agonists may play a significant role.
8 min read
GLP-1s, Liver Health, and Digestive Innovations: A Medical Update
This comprehensive update delves into groundbreaking research on GLP-1 receptor agonists and their impact on liver health, alongside crucial developments in inflammatory bowel disease (IBD) management and innovative approaches to digestive symptom relief. Discover how cutting-edge science is shaping patient care and explore practical implications for managing chronic conditions.
7 min read
Oral GLP-1s for Weight Loss Maintenance: A New Frontier
A groundbreaking study reveals that switching to an oral GLP-1 medication like orforglipron can help individuals maintain a significant portion of their weight loss achieved with injectable therapies, offering a new avenue for long-term obesity management.
6 min read
Eli Lilly 150 Years: AI, GLP-1 Advances & Future of Weight Loss
Eli Lilly celebrates 150 years with a focus on AI-driven manufacturing, new GLP-1 oral therapies, and expanded neuroscience research, signaling a major shift in pharmaceutical innovation.
8 min read
Semaglutide for Older Adults: Weight Loss & Heart Health Gains
A comprehensive analysis of the STEP trials reveals that once-weekly semaglutide significantly benefits older adults with obesity, leading to substantial weight loss and improvements in key cardiometabolic markers. This article delves into the findings, implications, and considerations for this important demographic.
7 min read
GLP-1 Obesity Drugs & Exercise: The Essential Partnership
While GLP-1 agonists offer remarkable weight loss, a new perspective highlights why exercise remains indispensable for long-term success and health benefits, addressing challenges in patient adherence.
7 min read
Antimicrobial Peptides: A New Link to Neurodegenerative and Amyloid Diseases
Discover the groundbreaking research linking antimicrobial peptides (AMPs) to neurodegenerative and amyloid diseases. This article delves into the shared mechanisms, bidirectional feedback loops, and potential new therapeutic strategies emerging from this exciting field.
8 min read
GLP-1 Weight Loss Drugs: The Risk of Stopping and Restarting
New research suggests that the effectiveness of popular GLP-1 weight loss medications may significantly diminish with intermittent use. Understand the implications for your health journey.
7 min read
GLP-1 Drugs: New Hope for Depression and Motivation?
A recent study published in JAMA Psychiatry has unveiled promising findings regarding GLP-1 receptor agonists, such as semaglutide, and their potential to address a core symptom of major depressive disorder: a lack of motivation. This article delves into the study's methodology, results, and the broader implications for mental health treatment.
8 min read
New AI-Discovered Molecule Offers Potential Ozempic/Wegovy Alternative
A groundbreaking discovery using artificial intelligence has identified a naturally occurring molecule, BRP, that targets the brain's appetite center, potentially offering a new and improved alternative for weight management compared to current GLP-1 medications.
7 min read
Preventing Weight Regain After GLP-1: The New Endoscopic Breakthrough
New research suggests an outpatient endoscopic procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Wegovy and Mounjaro.
3 min read
Severe Obesity and Heart Failure: New Insights into Cardiac Muscle Recovery
A groundbreaking Johns Hopkins study reveals that severe obesity causes intrinsic cardiac muscle weakness, but weight loss can trigger significant recovery.
3 min read
Tirzepatide vs. Semaglutide: A Comprehensive Guide to Cost and Health Outcomes
A new lifetime economic analysis suggests tirzepatide may offer superior long-term value and clinical outcomes compared to semaglutide for obesity management.
2 min read
Hidden Reason Ozempic Fails for Some: GLP-1 Resistance Revealed
New research reveals a hidden genetic reason why Ozempic fails for some: GLP-1 resistance linked to PAM gene variants affecting 10% of the population. Despite higher GLP-1 levels, these individuals show reduced drug efficacy in lowering blood sugar. Discover the study's findings from humans, mice, and clinical trials.
7 min read
Zydus, Lupin Partner to Launch Ozempic Rival Semaglutide in India
Zydus Lifesciences and Lupin are teaming up to bring Semaglutide injection to India, positioning it as a rival to Ozempic for type 2 diabetes and chronic weight management. Marketed by Zydus with a user-friendly reusable pen, this GLP-1 therapy offers new options for adults with poor glycemic control or obesity-related conditions. Here's what patients need to know about this launch.
5 min read
Eli Lilly's Orforglipron: More Effective GLP-1 Pill for Weight Loss?
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
6 min read
New GLP-1 Weight-Loss Drugs Stronger Than Wegovy and Zepbound
When Terra Field switched from Wegovy to Zepbound, her weight loss resumed after a plateau, silencing the 'food noise' she'd battled since childhood. Now, next-generation GLP-1 drugs like CagriSema and retatrutide promise even greater results by targeting multiple gut hormones. But as these stronger treatments advance, experts caution about the risks of losing too much weight too fast.
8 min read
Investor $100K Bet: Altimmune Pemvidutide vs Eli Lilly
Altimmune shares surged 35.4% after FDA granted Breakthrough Therapy Designation to pemvidutide for MASH treatment. Reddit investors, including one with a $100K position, hail it as a game-changer versus Eli Lilly's Mounjaro and Zepbound. This highlights promise in metabolic disease therapies.
2 min read
GLP-1 Drugs May Cut Airline Fuel Costs by $580M
GLP-1 weight loss drugs like Ozempic may trim airline fuel bills alongside waistlines. A Jefferies report estimates $580M annual savings for top US carriers from lighter passengers. Discover the science and implications.
2 min read
Viking Therapeutics Stock Surges on VK2735 Trial Success
Viking Therapeutics stock closed at $34.34, up 11.44%, fueled by VK2735 Phase 2 success. The trial delivered 14.7% average weight reduction, challenging GLP-1 leaders like Ozempic. Acquisition speculation boosts investor interest.
1 min read
Cutaneous Reactions Rare Yet Differ Among GLP-1 Receptor Agonists
Research on FDA adverse event reports indicates that cutaneous side effects from GLP-1 receptor agonists occur infrequently, with variation depending on the drug. Semaglutide reported the highest rates, while dulaglutide had the lowest. Monitoring and awareness are key for patients using these medications.
3 min read
Swift Weight Rebound and Erosion of Health Advantages Upon Discontinuing GLP-1s
Individuals regain their initial weight and shed all cardiometabolic improvements in less than two years following the cessation of semaglutide or tirzepatide, according to a comprehensive meta-analysis. The research underscores the rapid nature of this regain, occurring at a pace much quicker than after non-medication interventions. Experts stress the importance of sustained strategies for maintaining benefits in chronic obesity treatment.
6 min read
GLP-1 Receptor Agonists and Next-Generation Metabolic Hormone Therapies for Chronic Kidney Disease
Clinical trials across the cardiovascular-kidney-metabolic spectrum demonstrate kidney protective effects of incretin-based therapies. Multiple studies show GLP-1RAs and dual GIP/GLP-1RAs reduce kidney disease progression, albuminuria, and kidney failure risk in patients with type 2 diabetes and chronic kidney disease.
10 min read
India's 2026 Healthcare Plan: Prioritizing Drug Quality, Innovation, TB, and Obesity | Mint
India's healthcare roadmap for 2026 prioritizes enhancing drug quality, expanding digital health services, and addressing critical public health issues such as tuberculosis and obesity. The government aims to transform India into a global life sciences hub by focusing on innovation and stringent quality standards.
5 min read
Can Ozempic Be Used for Addiction Treatment?
The idea that Ozempic could treat addictions is gaining traction online, but it's crucial to examine the scientific basis for these claims. While some studies explore its impact on reward mechanisms, the drug's effects on the brain are not fully understood.
3 min read
Year in Review 2025: From Ozempic to Yeztugo; Significant New Drug Approvals and Their Importance
2025 saw the approval of several groundbreaking medications, transforming the management of chronic diseases and preventive care. These advancements offer new hope for patients and clinicians alike, addressing critical needs in various medical fields.
3 min read
Semax Peptide: Research on Neuroprotection, Inflammation, and Vascular Effects
Semax, a synthetic heptapeptide, has demonstrated neuroregulatory, neuroprotective, and immunomodulating properties in various research models. This article examines its biochemical characteristics, possible effects on gene expression, interactions with neurotransmitter systems, vascular modulation, metal binding, and utility in ischemia-reperfusion injury studies.
5 min read
Are Sexual Adverse Reactions Emerging With GLP-1 Receptor Agonists?
GLP-1 agonists, initially for blood sugar and weight loss, are now investigated for their impact on sexual function. Studies reveal diverse effects on libido, influenced by various factors. Some experience increased libido, while others report a decline.
4 min read
Reduced Gestational Diabetes Risk Observed with GLP-1 Use Before Pregnancy
A retrospective cohort study revealed that women taking GLP-1 receptor agonists before pregnancy exhibited a lower incidence of gestational diabetes. However, the study also indicated a potentially higher risk of pre-eclampsia in this group. These findings warrant further investigation due to the small sample size and potential confounding factors.
4 min read
Mounjaro Weight-Loss Injection Now Top-Selling Drug in India
According to recent data, Mounjaro, a drug for obesity and diabetes developed by Eli Lilly, has emerged as India's top-selling pharmaceutical brand. The medication's sales have surpassed those of long-time market leader Augmentin.
3 min read